Collaboration among clinicians, pharmacists, microbiologists, data scientists, and policymakers—alongside coordination by bodies such as Africa CDC—is vital for successful adoption. Furthermore, policymakers are urged to dedicate budget lines for digitizing surveillance, mandate minimum interoperability standards for public laboratory systems, and negotiate pooled licensing arrangements to reduce per-facility costs.
Conclusion and Future Outlook
Ultimately, while artificial intelligence holds genuine promise for strengthening antimicrobial stewardship in Africa, claims that these tools are already actively improving prescribing practices across the continent remain premature. Prospective clinical evidence demonstrating that AI interventions improve patient outcomes, prescribing habits, or resistance patterns is still scarce.
Realising this technological potential will require ongoing model development, rigorous local validation, implementation research, and careful assessment of clinical and economic outcomes. The commentary emphasizes that artificial intelligence must complement and strengthen existing stewardship programmes and national action plans rather than operate in isolation, requiring long-term commitment and coordinated investment to achieve tangible clinical benefits.
